FDA Policy/General

OMB Approves 11 FDA Info Collections

Federal Register notice: FDA has posted a list of recent information collections that have been approved by OMB. They are:

Food Labeling: Notification Procedures for Statements on Dietary Supplements
Guidance for Reagents for Detection of Specific Novel Influenza A Viruses
Mitigation Strategies to Protect Food Against Intentional Adulteration
Tropical Disease Priority Review Vouchers
Reporting Associated with New Animal Drug Applications and Veterinary Master Files
Substances Generally Recognized as Safe: Notification Procedure
Establishing and Maintaining Lists of S. Product Manufacturers/Processors With Interest in Exporting CFSAN-Regulated Products
Electronic Submission of Medical Device Registration and Listing
Accreditation of Third-Party Certification Bodies to Conduct Food Safety Audits and Issue Certifications
Sanitary Transportation of Human and Animal Food

To view the notice, click here.

Read more

Gupta Raises Concerns About Overton’s Independence, Ideology

FDA commissioner nominee Heidi Overton’s responses on vaccines, contraception and abortion medication during her 9/24 Senate confirmation hearing raise concerns that ideology could influence her decision-making if she takes over the agency, MSNBC senior medical analyst Dr. Vin Gupta said Friday. Gupta was particularly critical of Overton’

Overton Confirmation Remains Uncertain After Senate Hearing

FDA commissioner nominee Heidi Overton emerged from her Senate confirmation hearing Thursday (see earlier story) without resolving questions about whether she has enough Republican support to advance — and with a rapidly narrowing window for confirmation before the midterm elections. The Senate Health, Education, Labor and Pensions Committee hearing provided few

FDA Classifies Boston Scientific Imager II Catheter Recall as Class I

FDA has classified Boston Scientific's recall of its Imager II Angiographic Catheters as Class I because a manufacturing problem could cause catheter tips to degrade and detach, potentially resulting in life-threatening complications. The agency announced the Class I classification 9/25, updating an Early Alert it issued

FDA Approves Gazyva for Childhood-Onset Idiopathic Nephrotic Syndrome

FDA has approved Roche’s Gazyva (obinutuzumab) for reducing the risk of relapse in adults and children aged 2 and older with frequently relapsing or steroid-dependent, childhood-onset idiopathic nephrotic syndrome who are in remission. The expanded approval covers the use of the CD20-directed antibody beyond its existing